LGD-4033 is a selective androgen receptor modulator (SARMS), and a novel non steroidal oral SARM that binds to AR with high affinity and selectivity.
LGD-4033 is in a class of androgen receptor (AR) ligands that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss.
LGD-4033 is expected to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to tissue selective mechanism of action and an oral route of administration.